Antibodies targeting blood stage antigens of Plasmodium falciparum are associated with resistance to malaria infection and disease

Clicks: 9
ID: 327629
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #434 of 567 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 567 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Current licensed malaria vaccines are modestly protective against severe Plasmodium falciparum malaria but do not contain components which control blood stage infection. We evaluated the impact of antibodies to three blood stage candidate antigens (PfGARP, PfSEA-1, and PfGBP130) on P. falciparum infection and disease in a longitudinal cohort of children living in a holoendemic region of Western Kenya. Methods We enrolled and followed 266 children aged 2 to 7 years living in Western Kenya. Over the course of a 3-year follow-up period, we actively assessed their health status weekly, collected blood samples monthly to assess P. falciparum infection incidence and intensity, and measure IgG antibody levels to blood stage vaccine candidate antigens. Results Children with high levels of IgG antibodies to PfGBP130 or PfGARP, but not PfSEA-1, experienced 3.4- and 1.9- fold lower parasite densities respectively compared to those with low antibody levels (both P < 0.002). In addition, children with high levels of both anti-PfGBP130 and anti-PfGARP had significantly lower risk of clinical malaria compared to children with low antibody levels (HR: 0.58, 95% CI: 0.85-0.40). Over the 3-year follow-up period, individuals with elevated anti-PfGBP130 and anti-PfGARP antibody levels experienced an average of 4.51 cases of clinical malaria while those with lower levels experienced an average of 7.11 cases of clinical malaria (P = 0.005). Conclusions Higher antibody levels to PfGBP130 and PfGARP predict significantly lower parasite densities and lower risks of clinical malaria among 2- to 7-year-old children residing in a holoendemic area of Kenya.
Reference Key
openalex_W7208749402 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sangshin Park, Sunthorn Pond‐Tor, Fredrick Olewe, Christina Nixon, Ronald Stuart, Lei Zhang, Jennifer F. Friedman, Catherine S. Forconi, Ann Moormann, Boaz Odwar, Bernhards Ogutu, Hannah Wu, Dipak Kumar Raj, John Michael Ong’echa, Jonathan D. Kurtis
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag544
URL
https://doi.org/10.1093/cid/ciag544
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.